The article addresses the advancements in pharmacotherapy that are leading to new treatment options for various diseases, while simultaneously raising concerns about the rational financing of modern treatments. As new innovative drugs become available, it is increasingly critical to determine how to measure their real value and assess the cost-effectiveness of therapies. The upcoming panel discussion on "Cost-effectiveness of Innovations" during the 11th Health Challenges Congress in Katowice will focus on these issues, highlighting the need for effective evaluation methods.

This year's congress is centered around the theme "New Strategies for Health: Time to Redefine Goals and Challenges," and it aims to explore solutions that could help health care systems meet rising demographic, financial, technological, and climate challenges. The discussion on the cost-effectiveness of innovative therapies fits into this broader conversation, addressing a key question in contemporary medicine and health policy – how to ensure patient access to modern therapies while balancing financial constraints and advancing healthcare goals.

These deliberations are essential as healthcare systems face increasing pressures from an aging population and the continuous emergence of costly new treatments. By reassessing evaluation methodologies for innovative therapies, healthcare stakeholders can align financial resources better with patient needs and the overall effectiveness of treatments in the long run, thus promoting a more sustainable healthcare model.